Targeted delivery of a therapeutic entity using complementary ol

Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4241781, 5303911, 5303913, 5303919, A61K 5110, A61K 3944, C07K 1600, C07K 1700

Patent

active

057335230

ABSTRACT:
The invention relates to novel labelled modified oligonucleotides useful for anti-sense therapy, a conjugate of a targeting moiety, such as an antibody and a modified oligonucleotide complementary to the labelled oligonucleotide, the combination of both being useful in therapy of viral infections, tumours and (auto)immunodiseases. Also disclosed are pharmaceutical formulations comprising the various compounds.

REFERENCES:
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 5045451 (1991-09-01), Uhr et al.
Chemical Reviews, vol. 90, No. 4, Jun. 1990, American Chemical Society, E. Uhlmann et al., "Antisense Oligonucleotides: A New Therapeutic Principle".
Chemical Abstracts, vol. 112, No. 11, Mar., 1990, No. 95109K (Columbus, Ohio, US).
J.A. Fidanza et al., "Introduction of Reporter Groups at Specific Sites in DNA Containing Phosphorothioate Diesters," J.Am.Chem.Soc., 111, 1989, pp. 9117-9119.
Martindale, The Extra Pharmacopoeia, Ed. James Reynolds, 1989, p. 1380.
Canevari et al., Ann Oncol., vol. 5/8, pp. 698-901 (1994).
Hermentin, Behring Inst. Mitt, No. 82, pp. 197-215 (1988).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Targeted delivery of a therapeutic entity using complementary ol does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeted delivery of a therapeutic entity using complementary ol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeted delivery of a therapeutic entity using complementary ol will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-48936

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.